Skip to main content
Log in

Preliminary study of combination therapy with interferon-α and zinc in chronic hepatitis C patients with genotype 1b

  • Published:
Biological Trace Element Research Aims and scope Submit manuscript

Abstract

We have evaluated the efficacy of interferon-α (IFN-α) plus zinc therapy in hepatitis C patients with genotype 1b, poor responders for IFN alone. Ten patients were injected with 10 MU of IFN-α every day for 4 wk, followed by three times a week for 20 wk (control group). Nine patients took 300 mg of zinc sulfate a day orally during IFN-α therapy (zinc sulfate group), and 15 patients took IFN-α and 150 mg of polaprezinc (polaprezinc group).

On the d 8 of IFN therapy, circadian zinc levels in serum elevated significantly in the polaprezinc group compared to the zinc sulfate group or control group. Serum ALT levels normalized in 73.3% of the polaprezinc group, 55.6% of the zinc sulfate group, and 40.0% of the control group at 6 mo after the end of IFN therapy. Sustained eradication for the hepatitis C virus RNA judged at the end of the 6-mo follow-up period was higher in the polaprezinc group than in the zinc sulfate group (53.3% vs 11.1%, p<0.05) or the control group (20.0%). No clinical side effects of zinc were observed at the dose used. The data suggest that polaprezinc is expected to increase the therapeutic response of IFN-α for chronic hepatitis C with genotype 1b.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. G. L. Davis, L. A. Balart, E. R. Schiff, K. Lindsay, H. C. Bodenheimer, Jr., R. P. Perrillo, et al., Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter, randomized, controlled trial, N. Engl. J. Med. 321, 1501–1506 (1989).

    Article  PubMed  CAS  Google Scholar 

  2. A. M. Di Bisceglie, P. Martin, C. Kassianides, M. Lisker-Melman, L. Murray, J. Waggoner, et al., Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial, N. Engl. J. Med. 321, 1506–1510 (1989).

    Article  PubMed  Google Scholar 

  3. M. Shindo, A. Di Bisceglie, and J. Hoofnagel, Long term follow-up of patients with chronic hepatitis C treated with alfa-interferon, Hepatology 45, 1013–1016 (1992).

    Article  Google Scholar 

  4. M. L. Shiffman, C. M. Hofmann, V. A. Luketic, A. J. Sanyal, M. J. Contos, and A. S. Mills, Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose, Hepatology 24, 21–26 (1996).

    Article  PubMed  CAS  Google Scholar 

  5. K. L. Lindsay, G. L. Davis, E. R. Shiff, H. C. Bodenheimer, L. A. Balart, J. L. Dienstag, et al., Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial, Hepatology 24, 1034–1040 (1996).

    PubMed  CAS  Google Scholar 

  6. J. Y. Lau, G. L. Davis, J. Kniffen, K. P. Qian, M. S. Urdea, C. S. Chan, et al., Significance of serum hepatitis C virus RNA levels in chronic hepatitis, Lancet 341, 1501–1504 (1993).

    Article  PubMed  CAS  Google Scholar 

  7. N. N. Zein and D. H. Persing, Hepatitis C genotypes: current trends and future implications, Mayo. Clin. Proc. 71, 458–462 (1993).

    Article  Google Scholar 

  8. G. Rasi, D. DiVirgilio, M. G. Mutchnick, F. Colella, P. Sinibaldi-Vallebona, P. Piermarchi, et al., Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C, Gut 39, 679–683 (1996).

    PubMed  CAS  Google Scholar 

  9. O. Reichard, R. Schvarcz, and O. Weiland, Therapy of hepatitis C: alpha interferon and ribavirin, Hepatology 26(Suppl. 1), 108S-111S (1997).

    Article  PubMed  CAS  Google Scholar 

  10. F. Farinati, R. Cardin, N. De Maria, G. Della Libera, C. Marafin, E. Lecis, et al., Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis, J. Hepatol. 22, 449–456 (1995).

    Article  PubMed  CAS  Google Scholar 

  11. J. K. Olynyk, K. R. Reddy, A. M. Di Bisceglie, L. J. Jeffers, T. I. Parker, J. L. Radick, et al., Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C, Gastroenterology 108, 1104–1109 (1995).

    Article  PubMed  CAS  Google Scholar 

  12. A. Piperno, M. Sampietro, R. D’Alba, L. Roffi, S. Fargion, S. Parma, et al., Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C, Liver 16, 248–254 (1996).

    PubMed  CAS  Google Scholar 

  13. O. Beloqui, J. Prieto, M. Suarez, B. Gil, C. H. Qian, N. Garcia, et al., N-Acetyl cysteine enhances the response to interferon-αlfa in chronic hepatitis C: a pilot study, J. Interferon Res. 13, 279–282 (1993).

    PubMed  CAS  Google Scholar 

  14. R. J. Cousins, Absorption, transport and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin, Physiol. Rev. 65, 238–309 (1985).

    PubMed  CAS  Google Scholar 

  15. P. M. Hanna, M. B. Kadiiska, S. J. Jordan, and R. P. Mason, Role of metallothionein in zinc and chromium mediated tolerance to carbon tetrachloride hepatotoxicity: evidence against a trichloromethyl radical scavenging mechanism, Chem. Res. Toxicol. 6, 711–717 (1993).

    Article  PubMed  CAS  Google Scholar 

  16. M. Sato, J. Yamaki, T. Oguro, T. Yoshida, N. Nomura, and K. Nakajima, Induction of metallothionein synthesis by interferon α/β in response to zinc in mice, Tohoku J. Exp. Med. 178, 241–250 (1996).

    Article  PubMed  CAS  Google Scholar 

  17. B. D. Korant and B. E. Butterworth, Inhibition by zinc of rhinovirus protein cleavage: interaction of zinc with capsid polypeptides, J. Virol. 18, 298–306 (1976).

    PubMed  CAS  Google Scholar 

  18. Y. J. Gordon, Y. Asher, and Y. Becker, Irreversible inhibition of herpes simplex virus and procapsid synthesis by zinc ions, Antimicrob. Agents Chemother. 8, 377–380 (1975).

    PubMed  CAS  Google Scholar 

  19. E. Katz and E. Margalith, Inhibition of vaccina virus maturation by zinc chloride, Antimicrob. Agents Chemother. 19, 213–217 (1981).

    PubMed  CAS  Google Scholar 

  20. M. Ratka, M. Lackmann, C. Ueckermann, U. Karlins, and G. Koch, Poliovirus-associated protein kinase: destabilization of the virus capsid and stimulation of the phosphorylation reaction by Zn2+, J. Virol. 63, 3954–3960 (1989).

    PubMed  CAS  Google Scholar 

  21. Z. Y. Zhang, I. M. Reardon, J. O. Hui, K. L. O’Connell, R. A. Poorman, A. G. Tomasselli, et al., Zinc inhibition of renin and the protease from human immunodeficiency virus type 1, Biochemistry 10, 8717–8721 (1991).

    Article  Google Scholar 

  22. B. Yoffe, S. Pollack, E. Ben-Porath, O. Zinder, D. Barzilai, and H. Gershon, Natural killer cell activity in post-necrotic cirrhotic patients as related to hepatitis-B virus infection and plasma zinc levels, Immunol. Lett. 14, 15–19 (1986).

    Article  PubMed  CAS  Google Scholar 

  23. C. Driessen, K. Hirv, L. Rink, and H. Kirchner, Induction of cytokines by zinc ions in human peripheral mononuclear cells and separated monocytes, Lymphokine Cytokine Res. 13, 15–20 (1994).

    PubMed  CAS  Google Scholar 

  24. D. E. Poswillo and B. Cohen, Inhibition of carcinogenesis by dietary zinc, Nature 231, 447–448 (1971).

    Article  PubMed  CAS  Google Scholar 

  25. T. Nagamine, H. Takagi, Y. Hashimoto, H. Takayama, R. Shimoda, N. Nomura, et al., The possible role of zinc and metallothionein in the liver on the therapeutic effect of interferon-αlpha to hepatitis C patients, Biol. Trace Element Res. 58, 65–76 (1997).

    CAS  Google Scholar 

  26. H. Sano, S. Furuta, S. Totama, M. Miwa, Y. Ikeda, M. Suzuki, et al., Study on the metabolic fate of catena-(S)-[μ[N a-(3-aminopropionyl) histidinate(2-)-N 1,N 2,O:N τ]-zinc], Drug Res. 41(II), 965–975 (1991).

    CAS  Google Scholar 

  27. A. Miyoshi, H. Matsuo, G. Miwa, and M. Nakajima, Clinical evaluation of Z-103 in the treatment of gastric ulcer, Jpn. Pharmacol. Ther. 20, 181–197 (1992).

    Google Scholar 

  28. T. Yoshikawa, Y. Naito, T. Tanigawa, T. Yoneta, and M. Kondo, The antioxidant properties of a novel zinc-carnosine chelate compound, N-(3-aminopropionyl)-l-histidinate zinc, Biochem. Biophys. Acta 115, 15–22 (1991).

    Google Scholar 

  29. H. Okamoto, Y. Sugiyama, S. Okada, K. Kurai, Y. Akahane, Y. Sugai, et al., Detection of hepatitis C virus RNA typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources, J. Gen. Virol. 73, 673–679 (1992).

    Article  PubMed  CAS  Google Scholar 

  30. S. Karacyclin, A. Arcasoy, and O. Uzunalimoglu, Zinc plasma levels after oral zinc tolerance test in non-alcoholic cirrhosis, Dig. Dis. Sci. 30, 329–333 (1985).

    Article  Google Scholar 

  31. G. Fernandes, M. Nair, K. Onoe, T. Tanaka, R. Flyd, and R. A. Good, Impairment of cell-mediated immunity functions by dietary zinc deficiency in mice, Proc. Natl. Acad. Sci. USA 70, 457–461 (1979).

    Article  Google Scholar 

  32. M. Dardenne, J. M. Pleau, B. Nabarra, P. Lefrancier, D. M. Derrien, J. Choay, et al., Contribution of zinc and other metals to the biological activity of the serum thymic factor, Proc. Natl. Acad. Sci. USA 79, 5370–5373 (1982).

    Article  PubMed  CAS  Google Scholar 

  33. R. Kohen, Y. Yamamoto, K. C. Cundy, and B. N. Ames, Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain, Proc. Natl. Acad. Sci. USA 85, 3175–3179 (1988).

    Article  PubMed  CAS  Google Scholar 

  34. O. I. Arouma, M. J. Laughton, and B. Halliwell, Carnosine, homocarnosine and anserine: could they act as antioxidants in vivo? Biochem. J. 264, 863–869 (1989).

    Google Scholar 

  35. G. J. Fosmire, Zinc toxicity, Am. J. Clin. Nutr. 51, 225–227 (1990).

    PubMed  CAS  Google Scholar 

  36. H. H. Sandstead, Requirements and toxicity of essential trace elements, illustrated by zinc and copper, Am. J. Clin. Nutr. 61, 621S-624S (1995).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nagamine, T., Takagi, H., Takayama, H. et al. Preliminary study of combination therapy with interferon-α and zinc in chronic hepatitis C patients with genotype 1b. Biol Trace Elem Res 75, 53–63 (2000). https://doi.org/10.1385/BTER:75:1-3:53

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/BTER:75:1-3:53

Index Entries

Navigation